INBX · ISSUER CIK 2007919
Inhibrx Biosciences, Inc.
Between Jul 31, 2026 and Oct 28, 2026, 4 Inhibrx Biosciences, Inc. insiders reported $6.3M of open-market purchases and $279K of sales on SEC Form 4. The largest buyer was Lappe Mark (Chief Executive Officer, Director), with $4.5M.
↗4 insiders filed
Original Form 4 filings from Jul 31, 2026 to Oct 28, 2026. 0 of 2 sales were reported under a 10b5-1 plan.
$6.3MInsider buying
$279KInsider selling
+$6.1MNet open-market
Oct 14, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 14, 202618:58 | Oct 14, 2026 | INBX | Chief Executive Officer, Director | P · Buy | $84.56 | +10,040 | 170,000 | +6% | +$849K | -33.3% | -13.3% |
| Sep 28, 202617:47 | Sep 28, 2026from Sep 25, 2026 | INBX | Chief Executive Officer, Director | P · Buy | $99.88 | +10,000 | 740,548 | +1% | +$999K | -21.2% | -26.6% |
| Sep 23, 202616:59 | Sep 23, 2026 | INBX | Director | P · Buy | $100.00 | +5,000 | 434,360 | +1% | +$500K | -21.1% | -26.7% |
| Sep 17, 202617:46 | Sep 16, 2026 | INBX | Director | P · Buy | $100.00 | +5,000 | 429,360 | +1% | +$500K | -21.1% | -26.7% |
| Sep 15, 202617:52 | Sep 15, 2026from Sep 11, 2026 | INBX | Director | S · Sell | $109.03 | −1,500 | 7,500 | -17% | −$164K | ||
| Sep 10, 202619:06 | Sep 9, 2026from Sep 8, 2026 | INBX | Director | S · Sell | $115.47 | −1,000 | 9,000 | -10% | −$115K | ||
| Sep 8, 202617:23 | Sep 8, 2026 | INBX | Director | P · Buy | $113.52 | +5,000 | 424,360 | +1% | +$568K | -10.4% | -35.4% |
| Sep 8, 202616:26 | Sep 8, 2026 | INBX | Director | P · Buy | $114.65 | +2,500 | 227,064 | +1% | +$287K | -9.5% | -36.1% |
| Sep 8, 202616:04 | Sep 8, 2026 | INBX | Chief Executive Officer, Director | P · Buy | $105.82 | +25,000 | 730,548 | +4% | +$2.6M | -16.5% | -30.7% |